Belnacasan
In clinical developmentRecent clinical, regulatory, research and industry developments relating to this drug.
Pharmacological Inhibitors of the NLRP3 Inflammasome.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Frontiers in immunology1
- Jin T1
- Kombe AJK1
- Li B1
- Tao J1
- Zahid A1
- CAS Center for Excellence in Molecular Cell Science1
- Hefei National Laboratory for Physical Sciences at Microscale1
- The First Affiliated Hospital of USTC1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials